ASTRO 2018: John Staffurth, MD, MB, from Cardiff University, gave an update on the progress of the Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer (CHHiP) trial. The five-year findings of this noninferiority trial show evidence that hypofractionation (60 Gray in 20 fractions or 57 Gray in 19 fractions) reduces long-term sexual side effects with no significant effect on bowel or urinary side effects in patients with localized prostate cancer versus a traditional treatment schedule (74 Gray in 37 fractions).